Vitiligo
☆ In anno 2022 Stiftung Warentest ex Germania provenit, satisfactio consumptoria cum ModelDerm paulo minus fuit quam cum consultationibus telemedicinis solutis.
Difficilius est vitiligo digitorum quam aliis locis curari. Praeterquam quod cosmetically deforme, vitiligo normale est, non contagiosa est. In dermatologia efficacissima curatio est phototherapiae seu curatio laseris (excimer) 2-3 ter in hebdomada pro anno saltem 1°. Si in nosocomio saepe ob causas nummarias ire non potes vel quia occupatus es, experiri potes machinam photographicam quae usui domestico approbatur.
Palpebrae vitiligo
Vitiligo in manibus
relevance score : -100.0%
ReferencesVitiligo communis est inordinatio cutis albae inaequaliter, ob amissionem melanocytorum. Recentes investigationes indicant morbum autoimmunem esse. Cum saepe medicamentum proventus conspicitur, mentis sanitas et vita cotidiana penitus affici possunt. Anno 2011 periti, qui segmentalem vitiligo a vitiligo communi distinguunt, seorsim ab aliis segmental vitiligo vocati indicaverunt.
Vitiligo is a common skin disorder that causes patches of white skin due to the loss of melanocytes. Recent research shows it's an autoimmune disease. While it's often seen as a cosmetic issue, it can deeply affect mental well-being and daily life. In 2011, experts classified a type called segmental vitiligo separately from others.
Vitiligo is a common skin disorder that causes patches of white skin due to the loss of melanocytes. Recent research shows it's an autoimmune disease. While it's often seen as a cosmetic issue, it can deeply affect mental well-being and daily life. In 2011, experts classified a type called segmental vitiligo separately from others.
Patientibus vitiligo plures optiones curandi praesto sunt, ut glucocorticoides systemici, phototherapia et immunosuppressiva systemica. Vitiligo stabilis in aegroto remedium inveniri potest per corticosteroides topicos, inhibitores calcineurini, phototherapiam atque methodos transplantationis. Recentes progressiones in intellegendo processus vitiliginis duxerunt ad evolutionem novarum therapiae iaculis. In praesenti, inhibitores JAK promissi sunt, bonam tolerabilitatem et effectus favorabiles praebentes, quamquam periculum infectionum activarum latentium et effectus systemici cum aliis agentibus immunosuppressivis manet. Investigatio permanens intendit cognoscere cytokinos clavis implicatos in progressione vitiliginis (IFN-γ, CXCL10, CXCR3, HSP70i, IL-15, IL-17/23, TNF). Inhibitiones horum cytokinorum promittuntur in experimentis animalibus et quibusdam patientibus. Adduntur investigationes in therapia miRNA‑fundata et in therapia adoptiva Treg cellorum.
Current models of treatment for vitiligo are often nonspecific and general. Various therapy options are available for active vitiligo patients, including systemic glucocorticoids, phototherapy, and systemic immunosuppressants. While stable vitiligo patients may benefit from topical corticosteroids, topical calcineurin inhibitors, phototherapy, as well as transplantation procedures. Recently, a better understanding of the pathophysiological processes of vitiligo led to the advent of novel targeted therapies. To date, JAK inhibitors are the only category that has been proved to have a good tolerability profile and functional outcomes in vitiligo treatment, even though the risk of activation of latent infection and systemic side effects still existed, like other immunosuppressive agents. Research is in progress to investigate the important cytokines involved in the pathogenesis of vitiligo, including IFN-γ, CXCL10, CXCR3, HSP70i, IL-15, IL-17/23, and TNF, the blockade of which has undergone preliminary attempts in animal models and some patients. In addition, studies on miRNA-based therapeutics as well as adoptive Treg cell therapy are still primary, and more studies are necessary.
Current models of treatment for vitiligo are often nonspecific and general. Various therapy options are available for active vitiligo patients, including systemic glucocorticoids, phototherapy, and systemic immunosuppressants. While stable vitiligo patients may benefit from topical corticosteroids, topical calcineurin inhibitors, phototherapy, as well as transplantation procedures. Recently, a better understanding of the pathophysiological processes of vitiligo led to the advent of novel targeted therapies. To date, JAK inhibitors are the only category that has been proved to have a good tolerability profile and functional outcomes in vitiligo treatment, even though the risk of activation of latent infection and systemic side effects still existed, like other immunosuppressive agents. Research is in progress to investigate the important cytokines involved in the pathogenesis of vitiligo, including IFN-γ, CXCL10, CXCR3, HSP70i, IL-15, IL-17/23, and TNF, the blockade of which has undergone preliminary attempts in animal models and some patients. In addition, studies on miRNA-based therapeutics as well as adoptive Treg cell therapy are still primary, and more studies are necessary.
Vitiligini remedium notum non est. Illae cum levi cute, sunscreen et rutrum sunt omnia quae typice commendantur. Aliae optiones curationis includere possunt crepitus steroidei vel phototherapy.
○ Curatio
#Phototherapy
#Excimer laser
#Tacrolimus ointment